Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.

Completed

• Conditions: clear cell renal cell carcinoma; kidney cancer; 10038364

• Registration Number: NL-OMON35791
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

1. Age 18 years or older
2. Patients with clear cell renal cell carcinoma with metastases or patients with a low-grade neuro-endocrine tumor with metastases
3. Written informed consent

Exclusion Criteria

1. Use of L-dopa or SSRI
2. Patients with a second primary malignancy

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Difference in concentrations DA and 5-HT in thrombocytes of patients with clear<br /><br>cell renal cell carcinoma and healthy controls, and patients with low grade<br /><br>neuroendocrine tumours and healthy controls.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Difference in concentrations DA and 5-HT in thrombocytes of patients with clear<br /><br>cell renal cell carcinoma and low grade neuroendocrine tumours before start of<br /><br>a treatment cycle and during a treatment cycle.</p><br>